Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease
K Taylor M, Smith AN, Choi IY, Lee P, Kelly E, Arora T, Sullivan DK, Burns JM, Swerdlow RH, Wilkins HM
Alzheimer's & dementia (New York, N. Y.) · 1 cita
Etiquetas de revisión
Vínculos de autores con la industriaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Posiblemente financiado por la industria
- Organización sin fines de lucro
- Alzheimer's Association
- Gobierno
- National Institutes of Health
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NIA NIH HHS
- Organización sin fines de lucro
- Alzheimer's Association
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- Alzheimer's Association (AARG-22-924314); National Center for Advancing Translational Sciences (# UL1TR002366); National Institutes of Health (UL1 TR002366); National Institutes of Health (P30AG072973); National Institutes of Health (K01AG065487)
Según 5 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2026-01-01 · Alzheimers Dement (N Y) · vol. 12 · número 1 · pág. e70228
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 12% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 34 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Muscle metabolism and nutrition · Nutrition and Health in Aging · Diet and metabolism studies
- Palabras clave
- Pilot trial, Creatine, Bioenergetics, Disease, Clinical trial, Pilot program
10 autores
- Matthew K Taylor🇺🇸 · autor de correspondenciaAlzheimer’s Disease Neuroimaging Initiative; University of Kansas Medical Center
- Aaron N Smith🇺🇸University of Kansas Medical Center
- In‐Young Choi🇺🇸University of Kansas Medical Center
- Phil Young Lee🇺🇸University of Kansas Medical Center
- Emma Kelly🇺🇸University of Kansas Medical Center
- Tanu Arora🇺🇸University of Kansas Medical Center
- Debra K. Sullivan🇺🇸Alzheimer’s Disease Neuroimaging Initiative; University of Kansas Medical Center
- Jeffrey Murray Burns🇺🇸Alzheimer’s Disease Neuroimaging Initiative; University of Kansas Medical Center
- Russell Howard Swerdlow🇺🇸Alzheimer’s Disease Neuroimaging Initiative; University of Kansas Medical Center
- Heather Wilkins🇺🇸Alzheimer’s Disease Neuroimaging Initiative; University of Kansas Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Creatine monohydrate (CrM) may mitigate bioenergetic failure in Alzheimer's disease (AD) by supporting ATP buffering and modulating mitochondrial function. Building upon our previous findings that CrM is associated with increased brain creatine (Cr) and improved cognition in AD, we investigated our hypothesis that CrM is associated with improved bioenergetic biomarkers in AD.
Methods
In this single-arm pilot featuring participants with AD (n = 20, 35% female), we investigated changes in bioenergetic biomarkers after 8 weeks of CrM supplementation (20 g/day). We measured brain concentration of N-acetylaspartate (NAA) and glutathione (GSH) using 1H magnetic resonance spectroscopy. We measured platelet and lymphocyte mitochondrial respiration using Oroboros Oxygraph-2K respirometry, lymphocyte adenosine diphosphate (ADP) and adenosine triphosphate (ATP) using a bioluminescent assay, and lymphocyte reactive oxygen species (ROS) with flow cytometry using Amplex Red and MitoSOX. We also investigated sex-dependent bioenergetic responses.
Results
Brain NAA and GSH did not change. In females only, both platelet and lymphocyte mitochondrial respiration increased (p p p < 0.001) levels rose significantly in both sexes while ATP/ADP ratio, superoxide, and hydrogen peroxide remained stable.
Discussion
These data suggest CrM may augment systemic energy availability in both sexes and mitochondrial capacity in a sex-specific manner in AD. Interpretation of results from this pilot study is limited by lacking a control group, small sample size, and its relatively short timeframe. However, these preliminary findings support further investigation of CrM as a potential bioenergetic intervention in AD with well-designed RCTs, including exploration of potential sex-specific bioenergetic responses to CrM.
Trial registration
ClinicalTrials.gov, NCT05383833, registered on May 20, 2022.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.